Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy-Reference-Cited by-同舟云学术

Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy

Published:2017-07-05 Issue:7 Volume:12 Page:e0180628
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yang Shih-Hung,Lee Jen-Chieh,Guo Jhe-Cyuan,Kuo Sung-Hsin,Tien Yu-Wen,Kuo Ting-Chun,Cheng Ann-Lii,Yeh Kun-Huei^ORCID

Funder

Ministry of Health and Welfare

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. Global cancer statistics, 2012;LA Torre;CA Cancer J Clin,2015

2. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial;H Oettle;JAMA,2013

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;HA Burris 3rd;J Clin Oncol,1997

4. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer;V Heinemann;J Clin Oncol,2006

5. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group;E Poplin;J Clin Oncol,2009

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Awardee Summary of 2023 Taiwan Oncology Society Clinical Research Award Recipient: Persistent Endeavors on Research of Digestive Cancers for Three Decades;Journal of Cancer Research and Practice;2024-01

2. Potential of PAR-4 as a Therapeutic Target for Pancreatic Cancer;Tumor Suppressor Par-4;2021

3. Par-4 activation restrains EMT-induced chemoresistance in PDAC by attenuating MDM-2;Pancreatology;2020-12

4. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy;Science Advances;2020-02-28

5. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review;Cancer Treatment Reviews;2019-05